CSIMarket
 


Cellectar Biosciences inc   (CLRB)
Other Ticker:  
 

Cellectar Biosciences Inc 's Leverage Ratio

CLRB's quarterly Leverage Ratio and Total Liabilities, Equity growth


In III Quarter 2023 Cellectar Biosciences Inc had stockholder deficit.

Within Major Pharmaceutical Preparations industry Cellectar Biosciences inc achieved the lowest Leverage Ratio in the third quarter 2023. While total ranking remained the same in the third quarter 2023 compared to the previous quarter at no. .

Explain Leverage Ratio?
Who are CLRB Customers?
What are CLRB´s Total Liabilities?


CLRB Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change - - -73.04 % -53.07 % -66.96 %
Y / Y Total Liabilities Change 447.31 % 17.02 % 53.04 % 42.11 % 109.82 %
Leverage Ratio MRQ - - 0.94 0.35 0.5
CLRB's Total Ranking # # # # #
Seq. Equity Change - - -52.7 % 21.62 % -36.86 %
Seq. Total Liabilities Change 445.2 % -7.43 % 26.03 % -13.96 % 16.56 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Cellectar Biosciences Inc 's Equity $ -13 Millions Visit CLRB's Balance sheet
Cellectar Biosciences Inc 's Total Liabilities $ 35 Millions Visit CLRB's Balance sheet
Source of CLRB's Sales Visit CLRB's Sales by Geography


Cumulative Cellectar Biosciences Inc 's Leverage Ratio

CLRB's Leverage Ratio for the trailling 12 Months

CLRB Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth - - -73.04 % -53.07 % -66.96 %
Y / Y Total Liabilities TTM Growth 447.31 % 17.02 % 53.04 % 42.11 % 109.82 %
Leverage Ratio TTM 5.94 0.72 0.43 0.29 0.22
Total Ranking TTM
Seq. Equity TTM Growth - - -52.7 % 21.62 % -36.86 %
Seq. Total Liabilities TTM Growth 445.2 % -7.43 % 26.03 % -13.96 % 16.56 %


On the trailing twelve months basis During the 12 months period ending III Quarter 2023 company had stockholder deficit.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 29, during the past 12 months, other companies have achieved lower Leverage Ratio than Cellectar Biosciences Inc . While total ranking remained unchanged compared to previous 12 month period at no. 83.

Explain Leverage Ratio?
Who are CLRB Customers?
What are CLRB´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 30
Healthcare Sector # 39
Within the Market #


trailing twelve months Leverage Ratio Statistics
High Average Low
6.15 0.49 0.09
(Sep 30 2023)   (Sep 30 2021)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity

Date modified: 2023-11-14T19:43:38+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com